Equity Research Health Information Services

Should You Buy Schrödinger, Inc. Stock in 2026?

By CirclFi Research Team · · Updated · 3/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Schrödinger, Inc. (SDGR) occupies a solid middle-ground position with a Quality of Company score of 7.1/10. At the current market price of $23.25, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.

The short answer: 0 of 3 CirclFi valuation models project upside for Schrödinger, Inc. (SDGR) at $23.25 — the model consensus leans bearish, with a Quality Score of 7.1/10 and Value-Trap risk of 19/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 3 of 3 models suggest overvaluation — majority bearish
  • Quality Score: 7.1/10 — Strong — above-average quality
  • Value Trap Risk: 19/100 — Minimal — healthy fundamentals
  • Fair Value Range: $4.30 – $8.96 (108% spread)

Bullish Models

0 / 3

Bearish Models

3 / 3

Quality Score

7.1 /10

Strong — above-average quality

Value Trap Risk

19 /100
Minimal

Minimal — healthy fundamentals

Model Consensus

3 /13
Active Models

Avg. confidence: 41%

What Is the Investment Case for Schrödinger, Inc. (SDGR) in 2026?

What Is the Bull Case vs the Bear Case for Schrödinger, Inc. (SDGR)?

Bull case versus bear case for Schrödinger, Inc. (SDGR) at $23.25, derived from 3 active CirclFi valuation models on 2026-09-15.
Bull case Bear case — $4.30 target (-81.5%)
No active model projects meaningful upside for SDGR at $23.25. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. According to the CirclFi Deep Alpha Valuation Engine, the Bayesian DCF model sees the stock as overvalued with a fair value of $4.30 (-81.5%), suggesting that the market price embeds overly optimistic growth assumptions.

How Does SDGR Compare to Its Health Information Services Peers?

BTSG BrightSpring Health
7.2
NRC NRC Health
7.0
TDOC Teladoc Health, Inc.
7.3
DH Definitive Healthcar
7.0
SLP Simulations Plus, In
7.4
WEAV Weave Communications
6.6
PBSV Pharma-Bio Serv, Inc
5.9
BEAT HeartBeam, Inc.
4.7

Valuation data pages: BTSG · NRC · TDOC · DH · SLP · WEAV · PBSV · BEAT · SPOK · DOCS · HQY

See full Health Information Services rankings →

Which Other Stocks Score Like SDGR on Quality?

Closest companies to SDGR’s Quality of Company score of 7.1/10, across all industries.

Why Do CirclFi’s 3 Models Disagree on SDGR?

Spread

108%

Fair Value Range

$4.30 – $8.96

A 108% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

FTNN

$8.96 (-61.4%)

Most Bearish

Bayesian DCF

$4.30 (-81.5%)

What Are the Biggest Risks of Buying SDGR Stock?

Model Disagreement

108% spread signals high variance in projections.

Bearish Consensus

3/3 models suggest overvaluation.

Macro/Sector Risk

Health Information Services headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View SDGR Data Page →

So Is Schrödinger, Inc. (SDGR) Worth Buying in 2026?

Our valuation engine sends a clear cautionary signal on Schrödinger, Inc. at $23.25. 3/3 models flag overvaluation, median fair value sits at $5.32 (-77.1%), and the risk-reward profile appears unfavorable. Quality at 7.1/10 is the one bright spot, but premium quality at the wrong price can still destroy returns. This is a stock where patience — or avoidance — may be the optimal strategy.

These are quantitative model outputs, not investment recommendations. Schrödinger, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About SDGR Stock?

Should I buy SDGR stock right now?

Based on CirclFi's multi-model analysis, 0 of 3 models see upside for SDGR at $23.25. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Schrödinger, Inc.?

Key risks include: limited model coverage (3/13 active), reducing analytical confidence; wide model disagreement (108% spread), signaling high uncertainty; general market and sector-specific risks affecting Health Information Services companies. Always diversify and consult a financial advisor.

How does SDGR compare to its competitors?

Among Health Information Services peers, SDGR holds a Quality Score of 7.1/10. Comparable companies include BTSG (QOC 7.2), NRC (QOC 7.0), TDOC (QOC 7.3). The relative ranking helps investors identify whether SDGR offers better fundamental quality than alternatives in the same sector.

Is SDGR a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. SDGR's Quality Score of 7.1/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.

What price should I buy SDGR at?

CirclFi does not provide target buy prices or price alerts. However, our 3 active models produce fair value estimates ranging from $4.30 to $8.96. At $23.25, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for SDGR.

View SDGR Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →